+39 06 99775399 info@reithera.com
Languages
  • Italiano
  • English
The first Ebola Sudan vaccine doses to reach Uganda manufactured at ReiThera LEARN MORE
  • Home
  • About
  • R&D
  • CDMO
  • News
    • Grants
    • Press Release
    • Publications
    • Events
  • Contact
  • English
    • Italian
An ideal partner for your biotechnological journey An ideal partner for your biotechnological journey
  • Home
  • About
  • R&D
  • CDMO
  • News
    • Grants
    • Press Release
    • Publications
    • Events
  • Contact
  • English
    • Italian

Archives

Monthly Archive for: "January, 2022"
January 2022
0
By ef
In News, Publications
Posted January 25, 2022

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Originally published on npj Vaccines volume 6, Article number: 131 (2021). Chiara Agrati, Stefania Capone, Concetta Castilletti, Eleonora Cimini, Giulia Matusali, Silvia Meschi, Eleonora [...]

READ MORE
0
By ef
In News, Publications
Posted January 24, 2022

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Originally published on Sci Transl Med. 2021 Oct 26. doi: 10.1126/scitranslmed. abj1996.

READ MORE
0
By ef
In News, Publications
Posted January 23, 2022

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Originally published on Molecular Therapy Volume 29, Issue 8, 4 August 2021, Pages 2412-2423 Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, [...]

READ MORE
0
By ef
In News, Publications
Posted January 22, 2022

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Originally published on Science. 2021 Jan 29;371(6528):521-526. doi:10.1126/science.aax8819.PMID: 33510029. Capone S, Brown A, Hartnell F, Sorbo MD, Traboni C, Vassilev V, Colloca S, Nicosia A, [...]

READ MORE
0
By ef
In News, Publications
Posted January 21, 2022

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Originally published on PLoS neglected tropical diseases. 2020 Jul 15. 14(7): e0008459. doi: 10.1371/ journal. pntd.0008459. 

READ MORE
Our privacy

Privacy Policy and Cookie Law

Modello Organizzativo 231

Follow us
  • linkedin
  • facebook
  • instagram
  • twitter

ReiThera srl is a biotech company developing products based on gene delivery technologies for advanced therapies, from early development to final QP release.

© Copyright 2018 | Made with by